Evommune, Inc. (NYSE: EVMN) is a Healthcare company (Biotechnology) with a market capitalization of $290M. The Maz Rating grades it against the other companies in its sector.
Evommune, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.02, Evommune, Inc. trades at 1.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -43.5%, return on invested capital of -50.1% and a free cash flow yield of -31.5%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 8.23. Over the past 52 weeks the share price ranged from $4.94 to $33.20, with a beta of 0.96.
Evommune, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 3 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Evommune, Inc. (EVMN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.55% / 30% · (Cash+Inv) / Mkt Cap (36m) 82.3% / 30% · Interest income / Revenue 247900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.55% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 53.0% / 33% · Receivables / Mkt Cap (36m) 0.60% / 49% · Interest income / Revenue 247900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.55% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 53.0% / 33.33% · Receivables / Mkt Cap (24m) 0.60% / 33.33% · Interest income / Revenue 247900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.15% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 64.7% / 33.33% · Receivables / Avg Assets (4Q) 0.17% / 33.33% · Interest income / Revenue 247900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.63% / 33.33% · (Cash+ST Inv) / Total Assets 60.6% / 33.33% · (Cash+Recv) / Total Assets 61.3% / 33.33% · Interest income / Revenue 247900000.0% / 5% | Fail |
No. As of September 2026, Evommune, Inc. (EVMN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Evommune, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 247900000.0% of each dividend: Evommune, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.